LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hello fellow warriors! Another heatwave, another newsletter (but the two are not correlated!). Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.

Clinical Research

• Phase 2 Trial for Xaluritamig (AMG 509)​
  This phase 2 study, led by Thomas Jefferson University, evaluates the efficacy of xaluritamig (AMG 509) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have shown a suboptimal response to Pluvicto. Xaluritamig is a STEAP1-directed bispecific T-cell engager designed to bridge T cells and prostate cancer cells that express the STEAP1 protein, thereby inducing a targeted immune attack. The trial addresses a critical clinical gap for patients who require new therapeutic options after failing to get sufficient benefit from PSMA-targeted radioligand therapy.
  ​
• Phase 1 Trial for ASP388B​
  An ongoing first-in-human phase 1 study is testing ASP388B, an experimental anticancer drug, in patients with advanced solid tumors, including mCRPC. The trial is structured in two parts, with the initial phase focusing on dose finding and safety before expanding to assess potential antitumor effects in specific tumor groups. Because the drug is in early-stage testing, the primary focus is on monitoring dose-limiting toxicities and other standard safety measures to establish a usable dose range. Notably, the drug’s exact molecular target and mechanism of action have not been publicly disclosed, leaving it as a mechanistically opaque investigational agent.​
  ​
• Phase 1 Trial for FX-111​
  A new phase 1 trial has begun recruiting participants to evaluate FX-111, a selective degrader targeting ARon, the active form of the androgen receptor. While many current therapies primarily suppress signaling from the inactive receptor state, FX-111 is designed to remove the active receptor itself. The study specifically targets men with mCRPC who have already progressed on androgen deprivation therapy (ADT) and at least one prior potent receptor inhibitor. Although there is a theoretical possibility that targeting ARon could work without ongoing ADT, the current trial protocol still requires patients to maintain background androgen suppression.​
  ​
• Muscle Health and Mitochondrial Function Study​
  A clinical study involving 60 patients with advanced prostate cancer examined how muscle health and mitochondrial function influence a patient’s ability to tolerate androgen deprivation therapy (ADT). The research found that men with higher baseline endurance (VO2 peak) and stronger mitochondrial respiration were more resilient and reported better well-being when starting treatment. Interestingly, the study highlighted that muscle quality is a more reliable marker than muscle quantity, as high lean mass alone did not necessarily correlate with better patient outcomes. While most patients experienced expected side effects such as decreased lean mass and increased fat over six months, those in better metabolic shape at the start saw smaller declines in physical performance. These findings suggest that aerobic exercise may be particularly valuable for maintaining mitochondrial health and stamina during ADT. Resistance plus endurance training seems to be the winning combination.​
  ​

Preclinical Research & Reviews

• KAIST Helical Nanoparticle Platform​
  Researchers at KAIST have developed a novel nanoparticle platform that effectively turns cancer cells into their own “alarm system” by inducing severe internal stress. The platform utilizes a unique helical shape and positive charge that allows the particles to enter cancer cells more efficiently than standard structures, subsequently disrupting the mitochondria. This process triggers immunogenic cell death, causing the dying cancer cells to release danger signals that recruit the immune system to attack the tumor. Beyond activating the immune system, the nanoparticles can also deliver gene therapy cargo, such as siRNA, directly into the cells to further suppress tumor growth. In preclinical mouse models, this dual-action system successfully increased the presence of cytotoxic T cells within tumors and substantially reduced tumor growth.​

​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max